Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

Patricio G. Schlottmann, MD, discussed investigational imaging systems that may improve detection of peripheral diabetic retinal disease.

By: Patricio G. Schlottmann, MD

Retinal Physician May 18, 2026

Clinical Report: Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

Overview

Investigational ultrawidefield optical coherence tomography angiography (OCTA) devices demonstrate potential in enhancing the detection of peripheral diabetic retinal disease. These devices provide a non-invasive method for assessing diabetic retinopathy and macular edema without the need for pupil dilation.

Background

Diabetic retinal disease is a significant cause of vision impairment and blindness among diabetic patients. Early detection and management are crucial for preventing disease progression. The introduction of advanced imaging technologies like OCTA may improve diagnostic capabilities, particularly for peripheral retinal disease, which is often overlooked in standard examinations.

Data Highlights

No numerical data was provided in the source material.

Key Findings

OCTA can evaluate diabetic retinopathy and macular edema effectively without pupil dilation.
Ultrawidefield OCTA provides 24-mm images in a single capture, enhancing the assessment of peripheral retinal disease.
Data indicates OCTA is a good predictor of disease progression in diabetic eye disease.
OCTA is emerging as a complementary tool to traditional imaging methods like fluorescein angiography.
Recent studies support the utility of widefield OCTA for detecting peripheral nonperfusion areas, which may indicate a risk for subclinical neovascularization.

Clinical Implications

The use of investigational OCTA devices could significantly improve the management of diabetic retinal disease by allowing for earlier detection of peripheral disease. Clinicians should consider integrating these technologies into their practice to enhance patient outcomes.

Conclusion

Investigational OCTA devices show promise in improving the assessment and management of diabetic retinal disease, particularly in detecting peripheral complications. Continued research and validation are necessary to establish their role in clinical practice.

PentaVision

Retinal Physician